Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer

Deficient mismatch repair (dMMR)/microsatellite instability-high (MSIH) colorectal cancer is resistant to conventional chemotherapy but responds to immune checkpoint inhibition (ICI). We review the standard of care in locally advanced dMMR rectal cancer with a focus on ICI. We also present a case re...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Alan, Pedraza, Rodrigo, Kennecke, Hagen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136520/
https://www.ncbi.nlm.nih.gov/pubmed/37185392
http://dx.doi.org/10.3390/curroncol30040279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136520/
https://www.ncbi.nlm.nih.gov/pubmed/37185392
http://dx.doi.org/10.3390/curroncol30040279

Ejemplares similares